Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.


Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be… (More)
DOI: 10.1200/JCO.2014.58.8848